Apr 08, 2025 7:00am EDT Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
Mar 06, 2025 7:00am EST Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
Feb 11, 2025 7:00am EST Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
Feb 05, 2025 7:00am EST Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
Jan 06, 2025 7:00am EST Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
